Compare AbbVie Inc (ABBV) vs Futu Holdings Ltd (FUTU) Price & Performance

AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.

The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.

FUTU trades at $94.03, down 1.06% on the day, with a neutral technical signal and bearish moving averages. The company reported strong revenue growth to $22.85B in 2025 and a net income margin of 41.83%, but faces multiple securities class action lawsuits alleging fraud related to undisclosed regulatory penalties. Valuation ratios appear attractive with a P/E of 10.85 and EV/EBITDA of 7.16.

The outlook is clouded by legal risks and mixed earnings performance, with recent misses on EPS estimates. Analyst consensus remains positive with 58% buy ratings, but investors must weigh solid fundamentals against significant litigation overhangs and regulatory scrutiny that could impact future performance.